Omeros (OMER) said Friday that clinical trial site activation for enrollment is underway for its phase 3 program evaluating zaltenibart as a possible treatment for paroxysmal nocturnal hemoglobinuria.
A total of 120 clinical sites across 30 countries have been chosen for participation in the zaltenibart phase 3 program, the company said, adding that data needed for submission of the biologics licensing application remains on track for Q4 of 2026
Omeros shares were 1.2% higher in recent trading.
Price: 9.21, Change: +0.11, Percent Change: +1.21
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。